DXCM SHAREHOLDER ALERT: Contact BFA Law by October 21 about the Securities Fraud Class Action Lawsuit if You Lost Money on Your DexCom, Inc. Investment (NASDAQ:DXCM)

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives.

If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in DexCom securities.   The case is pending in the U.S. District Court for the Southern District of California and is captioned Alonzo v. DexCom, Inc., No. 24-cv-01485.

What is the Lawsuit About?

DexCom develops glucose monitoring systems for diabetes management. The company discussed its ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year’s gross margins, while scaling customer conversion to the new G7 platform.

After the market closed on July 25, 2024, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. The news caused a precipitous decline in the price of DexCom stock. The price of the company’s stock closed at $107.85 per share on July 25, 2024. Prior to the market open on July 26, 2024, DexCom stock was trading in the range of $66.60 per share, a decline of $41.25 per share, or 38%.

Click here for more information: https://www.bfalaw.com/cases-investigations/dexcom-inc.

What Can You Do?

If you invested in DexCom, Inc. you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/dexcom-inc

Or contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/dexcom-inc

Attorney advertising. Past results do not guarantee future outcomes.